Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2003

View Archived Issues

New drug with potential in the management of preterm uterine activity

Tacrolimus could improve liver function after liver transplantation

Bezafibrate diminishes insulin resistance and improves lipid metabolism in hypertriglyceridemia

LY-333531 reduces diabetic hyperalgesia

KF-24345: an adenosine uptake inhibitor with antiinflammatory properties

Roxithromycin has antiallergic activity

Lilly presents new melanocortin MC4 agonists in a recent patent

BMS scientists prepare novel HIV reverse transcriptase inhibitors

FDA approval for Gamunex

Pharmacia patent covers novel oxazolidinone-based antibacterial agents

Potent and selective CDK4 inhibitors identified by Warner-Lambert researchers

Dainippon licenses AC-3933 to Aventis

Novel HCV NS3 protease inhibitors in early development at Schering-Plough

SCRAS describes dual lipid peroxidation inhibitors/sodium channel modulators and their use

New dosage strengths approved for Avandamet

NICE recommends first-line treatment with Glivec for newly diagnosed CML patients

Schering AG plans phase III Crohn's disease study of Leukine

Syn X Pharma finalizes Alzheimer's agreement with Ortho-Clinical Diagnostics

Phase I study evaluates new breast cancer detection method

Enrollment commences in phase I trial of Dacogen plus Proleukin for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...